For what?How many lawsuits do u think HR is dealing with? Just curious. Horrible company.
Hhr is not friensdFor what?
Turnover is sky high, pipeline is empty, morale is rock bottom, yet the numbers (especially ex - US) are very good. The performance of Galderma defies logic. Can someone help explain what’s going on?What does 2025 look like? Any company with significant turnover just can’t make it on this day and age. What does future hold?
Dude - do you not know the history?! LOE on huge med derm brands 2018-2020, nestle’s sale to private equity in 2019 holds up bringing Nemo to market, then pandemic slows everything down. Also - pandemic hurt the elective filler/toxin/fake face category…Once upon a time - not so long ago - the US was the largest market for Galderma. These time are long gone. International, ie all markets ex-US now represent the bulk of sales and are growing at 13% whilst you are delivering 2.5%.
We’re all struggling with incompetent leadership and low morale. Please do better.
What makes you think Nemo will ever get to full speed? We launch with restricted distribution and are expecting an atopic dermatitis indication in a month? Good luck trying to get use at any IDN that has access to literally every other AD product.Dude - do you not know the history?! LOE on huge med derm brands 2018-2020, nestle’s sale to private equity in 2019 holds up bringing Nemo to market, then pandemic slows everything down. Also - pandemic hurt the elective filler/toxin/fake face category…
It’s about damn time the international segment stopped riding the US coattails! We appreciate the help keeping the ship steady! For that, big thanks!
Once Nemo is running a full speed, you’ll be riding coattails again!
Do better with your “opinions”… context is king!
International markets were hit with earlier LOE, the same divestment to private equity and was worse hit in the elective category during COVID…..so that’s not the explanation. Try again dude…and take some responsibility.Dude - do you not know the history?! LOE on huge med derm brands 2018-2020, nestle’s sale to private equity in 2019 holds up bringing Nemo to market, then pandemic slows everything down. Also - pandemic hurt the elective filler/toxin/fake face category…
It’s about damn time the international segment stopped riding the US coattails! We appreciate the help keeping the ship steady! For that, big thanks!
Once Nemo is running a full speed, you’ll be riding coattails again!
Do better with your “opinions”… context is king!
